Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease

Aging

Volumn 6, Issue 4, 2014, Pages 311-319

  Tonne, Jason M ^a   Holditch, Sara J ^a   Oehler, Elise A ^a   Schreiber, Claire A ^a   Ikeda, Yasuhiro ^a   Cataliotti, Alessandro ^a  

^a MAYO CLINIC   (United States)

Author keywords

AAV9; BNP; Hypertension; Natriuretic peptide; Survival

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADENOVIRIDAE; ANIMAL; COMPLICATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEART DISEASES; HYPERTENSION; MALE; PROCEDURES; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADENOVIRIDAE; ANIMALS; GENETIC THERAPY; GENETIC VECTORS; HEART DISEASES; HYPERTENSION; MALE; NATRIURETIC PEPTIDE, BRAIN; RATS; RATS, INBRED SHR; TRANSDUCTION, GENETIC;

EID: 84900470385     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100655     Document Type: Article

References (50)

1. Braunwald E, Harrison DC, Chidsey CA. The Heart as an Endocrine Organ. The American journal of medicine. 1964; 36: 1-4.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988; 332: 78-81.
3. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981; 28: 89-94.
4. Potter LR, Hunter T. Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. The Journal of biological chemistry. 2001; 276: 6057-6060.
5. Huntley BK, Sandberg SM, Noser JA, et al. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. Journal of cellular physiology. 2006; 209: 943-949.
6. Hawkridge AM, Heublein DM, Bergen HR, 3rd, Cataliotti A, Burnett JC, Jr., Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102: 17442-17447.
7. Hawkridge AM, Muddiman DC, Hebulein DM, Cataliotti A, Burnett JC, Jr. Effect of plasma protein depletion on BNP-32 recovery. Clinical chemistry. 2008; 54: 933-934.
8. Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nature genetics. 2009; 41: 348-353.
9. Belluardo P, Cataliotti A, Bonaiuto L, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006; 291: H1529-1535.
10. Cataliotti A, Macheret F, McKie PM, et al. Deficiency of the cardiorenal protective hormone BNP in early stages of hypertension. Journal of Hypertension. 2010; 28: E21-E21.
11. Macheret F, Heublein D, Costello-Boerrigter LC, et al. Human Hypertension Is Characterized by a Lack of Activation of the Antihypertensive Cardiac Hormones ANP and BNP. Journal of the American College of Cardiology. 2012; 60: 1558-1565.
12. Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011; 123: 1297-1305.
13. Kishimoto I, Tokudome T, Horio T, Garbers DL, Nakao K, Kangawa K. Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A: An Endogenous Protective Mechanism of the Heart. Curr Cardiol Rev 5: 45-51.
14. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circulation research. 2002; 91: 1127-1134.
15. Moilanen AM, Rysa J, Mustonen E, et al. Intramyocardial BNP gene delivery improves cardiac function through distinct context-dependent mechanisms. Circ Heart Fail. 2011; 4: 483-495.
16. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97: 4239-4244.
17. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. The New England journal of medicine. 2001; 345: 1291-1297.
18. Gems D, Partridge L (2013) Genetics of longevity in model organisms: debates and paradigm shifts. Annu Rev Physiol. 2013; 75: 621-644.
19. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?". Aging. 2012; 4: 861-877.
20. Gems D, de la Guardia Y. Alternative Perspectives on Aging in Caenorhabditis elegans: Reactive Oxygen Species or Hyperfunction? Antioxid Redox Signal. 2013; 19: 321-329.
21. Soesanto W, Lin HY, Hu E, et al. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension; 2009; 54: 1321-1327.
22. Flynn JM, O'Leary MN, Zambataro CA, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell. 2013; 12: 851-862.
23. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell. 2014; Epub ahead of print.
24. Xu X, Roe ND, Weiser-Evans MC, Ren J. Inhibition of Mammalian Target of Rapamycin With Rapamycin Reverses Hypertrophic Cardiomyopathy in Mice With Cardiomyocyte-Specific Knockout of PTEN. Hypertension. 2014; 63: 729-739.
25. Pravenec M, Kazdova L, Landa V, et al. Identification of mutated Srebf1 as a QTL influencing risk for hepatic steatosis in the spontaneously hypertensive rat. Hypertension. 2008; 51: 148-153.
26. Khan AM, Cheng S, Magnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011; 96: 3242-3249.
27. Heinisch BB, Vila G, Resl M, et al. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia. 2012; 55: 1400-1405.
28. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2000; 14: 1345-1351.
29. Hsu JH, Liou SF, Yang SN, et al. B-type natriuretic peptide inhibits angiotensin II-induced proliferation and migration of pulmonary arterial smooth muscle cells. Pediatr Pulmonol. 2013; Epub ahead of print.
30. Sun Y, Deng T, Lu N, Yan M, Zheng X. B-type natriuretic peptide protects cardiomyocytes at reperfusion via mitochondrial calcium uniporter. Biomed Pharmacother. 2010; 64: 170-176.
31. Gao P, Qian DH, Li W, Huang L. NPRA-mediated suppression of AngII-induced ROS production contribute to the antiproliferative effects of B-type natriuretic peptide in VSMC. Mol Cell Biochem. 2009; 324: 165-172.
32. Chiurchiu V, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P, Baldini PM. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept. 2008; 148: 26-32.
33. Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. The Journal of clinical investigation. 2012; 122: 1022-1036.
34. Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. The New England journal of medicine. 2008; 359: 158-165.
35. Okada Y, Shibazaki K, Kimura K, et al. Brain natriuretic peptide is a marker associated with thrombus in stroke patients with atrial fibrillation. J Neurol Sci. 2011; 301: 86-89.
36. Sadanaga T, Kohsaka S, Mitamura H, Ogawa S. Elevated Btype natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels. 2011; 26: 530-535.
37. Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 107: I9-16.
38. Shen S, Troupes AN, Pulicherla N, Asokan A. Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. Journal of virology. 2013; 87: 13206-13213.
39. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Molecular therapy: the journal of the American Society of Gene Therapy. 2006; 14: 316-327.
40. Grieger JC, Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol. 2012; 507: 229-254.
41. Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. 2013; 5: 194-192
42. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. The New England journal of medicine. 2011; 365: 2357-2365.
43. Ashtari M, Cyckowski LL, Monroe JF, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. The Journal of clinical investigation 121: 2160-2168.
44. Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Molecular therapy: the journal of the American Society of Gene Therapy. 2012; 20: 443-455.
45. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011; 124: 304-313.
46. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. Journal of cardiac failure. 2009; 15: 171-181.
47. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circulation research; 2006; 99: e3-9.
48. Bostick B, Ghosh A, Yue Y, Long C, Duan D. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene therapy. 2007; 14: 1605-1609.
49. Cataliotti A, Costello-Boerrigter LC, Chen HH, Textor SC, Burnett JC, Jr. Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clinic proceedings. 2012; 87: 413-415.
50. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125: 1635-1642.